Rhinomed Ltd
ASX:RNO
EV/EBIT
Enterprise Value to EBIT
Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.
Market Cap | EV/EBIT | ||||
---|---|---|---|---|---|
AU |
Rhinomed Ltd
ASX:RNO
|
11.4m AUD | -2 | ||
JP |
N
|
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
|
776 550.9T JPY | -5 046 864.6 | |
US |
Eli Lilly and Co
NYSE:LLY
|
734.8B USD | 66.7 | ||
DK |
Novo Nordisk A/S
CSE:NOVO B
|
4T DKK | 36.8 | ||
UK |
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP | 17 702.3 | ||
US |
Johnson & Johnson
NYSE:JNJ
|
371.4B USD | 15.5 | ||
US |
Merck & Co Inc
NYSE:MRK
|
330.7B USD | 58.3 | ||
UK |
AstraZeneca PLC
LSE:AZN
|
187.4B GBP | 278.3 | ||
CH |
Roche Holding AG
SIX:ROG
|
188.8B CHF | 11 | ||
CH |
Novartis AG
SIX:NOVN
|
182.6B CHF | 12.8 | ||
US |
Pfizer Inc
NYSE:PFE
|
161.2B USD | 20.5 |
EV/EBIT Forward Multiples
Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.